Company Analysis
Sign in

Eupraxia Pharmaceuticals Inc. (EPRX)

Nasdaq: EPRX · Pharmaceutical Preparations · Victoria, BC · filing with the SEC since 2013
Full chart Alerts Compare
Grade6.5
◀ Past 5.9● Present 5.7▶ Future 7.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$0.00
Net income-$38.6M-51.3%
Earnings per share$-1.03-35.5%
Operating cash flow-$28.6M+4.8%
Cash$80.6M+143.4%
Debtn/a
Shareholders’ equity$80.4M+152.7%
Shares, diluted40.0M+17.8%
Return on equity-47.9%
The recordfrom its filings
Filings in 202648
Newest filingNov 12 · S-8
Annual reportMar 13, 2026
Quarterly reportn/a
Next report due40-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted2
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
22232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SUPPL
Form SUPPL
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton EPRX · research, not advice